Search Within

Alexander Noor Shoushtari

  1. "Biomed Central Ltd"
Formats
  1. Meeting Abstract (12)
  2. Journal Article (9)
Groups
  1. Department of Medicine (21)
  2. Hematologic Malignancies, Division of (21)
  3. Melanoma Disease Management Team (21)
  4. Melanoma and Immunotherapeutics Service (21)
  5. Solid Tumor Oncology Division (21)
  6. GSK Faculty (5)

More Groups

People
  1. Jedd Wolchok (4)
  2. Margaret Callahan (3)
  3. Claire Friedman (2)
  4. Katherine Panageas (2)
  5. Michael Postow (2)
  6. Paul Chapman (2)

More People

Years
  1. 2024 (2)
  2. 2023 (1)
  3. 2022 (5)
  4. 2021 (4)
  5. 2020 (3)
  6. 2019 (3)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (17)
  2. Journal of Translational Medicine (4)
Publishers
  1. Biomed Central Ltd (21)

Results (21)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical benefit with tebentafusp in a patient with GNAQ mutant metastatic blue nevus-associated melanoma
    Journal Article

    Kudelka, M. R.; Richards, A. L.; Friedlander, P.; Wolchok, J. D.; Moy, A. P.; Shoushtari, A. N.
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma
    Journal Article

    Sacco, J. J.; Carvajal, R. D.; Butler, M. O.; Shoushtari, A. N.; Hassel, J. C.; Ikeguchi, A.; Hernandez-Aya, L.; Nathan, P.; Hamid, O.; Piulats, J. M.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: A phase 1 study
    Journal Article

    Hamid, O.; Hassel, J. C.; Shoushtari, A. N.; Meier, F.; Bauer, T. M.; Salama, A. K. S.; Kirkwood, J. M.; Ascierto, P. A.; Lorigan, P. C.; Mauch, C.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Repeat dosing of oncolytic adenovirus ONCOS-102 is associated with enhanced and persistent immune responses and improved systemic activity in anti-PD-1 resistant/refractory (R/R) melanoma
    Meeting Abstract

    Shoushtari, A.; Ottesen, L.; Levitsky, V.; Hansen, T. B.; Hornyak, T.; Olszanski, A.; Nyakas, M.; Wolchok, J.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
    Journal Article

    Bhave, P.; Ahmed, T.; Lo, S. N.; Shoushtari, A.; Zaremba, A.; Versluis, J. M.; Mangana, J.; Weichenthal, M.; Si, L.; Lesimple, T.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma
    Meeting Abstract

    Piperno-Neumann, S.; Hassel, J. C.; Rutkowski, P.; Baurain, J. F.; Butler, M. O.; Schlaak, M.; Sullivan, R. J.; Ochsenreither, S.; Dummer, R.; Kirkwood, J. M.; more...
    Journal of Translational Medicine (2022)

    Fulltext@MSK | Save
  • Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe vs. investigator's choice (IC) in first line metastatic uveal melanoma
    Meeting Abstract

    Hassel, J. C.; Rutkowski, P.; Baurain, J. F.; Butler, M. O.; Schlaak, M.; Sullivan, R. J.; Ochsenreither, S.; Dummer, R.; Kirkwood, J. M.; Joshua, A. M.; more...
    Journal of Translational Medicine (2022)

    Fulltext@MSK | Save
  • Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: Clinical outcomes and translational biomarker analyses
    Journal Article

    Friedman, C. F.; Spencer, C.; Cabanski, C. R.; Panageas, K. S.; Wells, D. K.; Ribas, A.; Tawbi, H.; Tsai, K.; Postow, M.; Shoushtari, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp
    Meeting Abstract

    Sacco, J.; Carvajal, R.; Butler, M.; Shoushtari, A.; Hassel, J.; Ikeguchi, A.; Hernandez-Aya, L.; Nathan, P.; Hamid, O.; Piulats, J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Results from phase IB study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM)
    Meeting Abstract

    Hamid, O.; Hassel, J.; Shoushtari, A.; Meier, F.; Bauer, T.; Salama, A.; Kirkwood, J.; Ascierto, P.; Lorigan, P.; Mauch, C.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save